DKSH Holding AG Expands Precision Healthcare in Asia with Launch of LIFE-SEQ Genomic Program in Thailand
Reuters
Sep 15
DKSH Holding AG Expands Precision Healthcare in Asia with Launch of LIFE-SEQ Genomic Program in Thailand
DKSH Holding AG, a leading provider of market expansion services, has announced a significant expansion in the realm of genomic healthcare by partnering with PacBio and Chulalongkorn University to launch "LIFE-SEQ," Asia's first genomic program for precision health. This initiative utilizes advanced HiFi genome sequencing technology to offer lifelong care starting from newborn screening and rare disease detection. As the exclusive distributor of PacBio in Thailand, DKSH is facilitating access to this cutting-edge technology and has assembled a team of genomics experts. In its initial phase, the program will provide free sequencing for 300 newborns at Chulalongkorn University's Faculty of Medicine, with plans to expand nationwide. This expansion marks a milestone in precision healthcare, aiming to deliver genomic benefits for people of all ages across Thailand.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. DKSH Holding AG published the original content used to generate this news brief on September 15, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.